Efficacy and safety of Qianlieshutong Capsules in the treatment for Type III prostatitis: A post-marketing, multicenter, randomized, double-blind, single-dummy, active-controlled, parallel-group clinical trial.

In 30 seconds

This multicenter, randomized, double-blind trial evaluated the efficacy and safety of Qianlieshutong Capsules (QLSTCs) combined with tamsulosin in 240 men with Type III prostatitis. The combination therapy resulted in a significantly greater reduction in the NIH-CPSI total score at week 8 compared to tamsulosin alone (14.30 ± 0.53 vs. 10.60 ± 0.54; mean difference = 3.70, P < 0.0001).

Key findings

• The combination group had a mean NIH-CPSI score reduction of 14.30 ± 0.53 compared to 10.60 ± 0.54 in the control group.
• The effective response rate was significantly higher in the combination group.
• Improvements were significant across all NIH-CPSI domains at week 8.
• Adverse event rates were low and comparable between the two groups (10.00% vs. 9.24%).

Why it matters

Chronic prostatitis/chronic pelvic pain syndrome is a challenging condition with limited treatment options. This study suggests that combining QLSTCs with tamsulosin may enhance symptom relief, offering a potential new approach for managing this condition.